Galectin Therapeutics GALT 深 滬
等待開盤 11-04 09:30:00 美东时间
6.00
+0.190
+3.27%
華盛通- 最 高6.02
- 今 開5.65
- 成交量 58.29万股
- 最 低 5.60
- 昨 收 5.81
- 總市值 3.84亿
- 52周最高 6.55
- 市盈率 靜 --
- 換手率 0.91%
- 52周最低 0.726
- 委 比 -32.09%
- 總股本 6406.03万
- 歷史最高 19.11
- 量 比 1.11
- 振 幅 7.23%
- 歷史最低 0.49
- 每 手 1
- 風險率 1.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多PureTech Health To Share New Data From Ongoing Phase 1b Clinical Trial Evaluating LYT-200, Anti-Galectin-9 Monoclonal Antibody, In r/rAML At ASH 2025
LYT-200 continues to demonstrate strong evidence of clinical activity, survival benefit and a highly favorable safety profile in heavily pretreated relapsed/refractory AML patients, both as a monotherapy and in
11-03 22:18
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025
<p><p align="justify">**Galectin Therapeutics Inc. (NASDAQ: GALT)** announced its participation in the **AASLD Liver Meeting 2025** held in **Washington, DC, USA, November 7-11, 2025**. The company will present **two sessions** related to the **NAVIGATE trial assessing belapectin** for treating **MASH cirrhosis**:</p><p align="justify">- **Oral Presentation:** Highlighting belapectin's ability to reduce liver stiffness and prevent varices over 18...
10-07 12:00
Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday. Shares of Stitch Fix, Inc. (NASDAQ: SFIX) dipped 7.6% to $5.21 in pre-market trading following the release of fourth-quarter results.
09-25 20:24
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Check-Cap (NASDAQ:CHEK) stock rose 25.5% to $2.66 during Monday's afte...
09-16 05:06
Galectin Therapeutics Highlights Promising Belapectin Results
An update from Galectin Therapeutics ( ($GALT) ) is now available. On September...
09-08 20:21
Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Galectin Therapeutics, Inc. announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025, in New York. The company presentation will take place on September 8 at 1:00 PM ET and will be available via live and archived webcast. Galectin's management, including CEO Joel Lewis and CMO Khurram Jamil, M.D., will also be available for one-on-one meetings. The company is focused on developing therapi...
09-02 12:00
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $6 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $6 price target.
08-14 23:51
Galectin Therapeutics Q2 EPS $(0.12) Beats $(0.16) Estimate
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 25 percent. This is a 40 percent increase over losses of $(0.20) per share from
08-14 20:09
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update
**Galectin Therapeutics公司发布2025年上半年财务报告**：公司报告了截至2025年6月30日的三个月和六个月的财务结果和业务更新。Galectin Therapeutics的首席执行官Joel Lewis表示，NAVIGATE试验的持续数据分析进一步支持了Belapectin在MASH肝硬化患者中的临床效果。Belapectin在减少肝纤维化进展和食管静脉曲张方面的效果在超过18个月的治疗中仍然显著。公司相信这些发现表明Belapectin有潜力改变疾病进展。公司预期在2025年下半年公布更多生物标志物数据，并继续与美国FDA沟通。截至2025年6月30日，公司现金和现金等价物为1380万美元，并通过股东提供的额外1000万美元债务融资，支持运营至2026年下半年。第二季度研发费用为330万美元，较2024年同期下降。
08-14 12:00
Galectin Therapeutics Secures $10M Credit Line for Growth
The latest announcement is out from Galectin Therapeutics ( ($GALT) ). On July ...
07-09 20:16
